Strides Pharma Science arm gets USFDA nod for pain relieving drug
Strides Pharma Science arm gets USFDA nod for pain relieving drug
New Delhi, Feb 24: Drug firm Strides Pharma Science on Wednesday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Ibuprofen Oral Suspension, used to relieve pain.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Children’s Motrin Oral Suspension, 100 mg/mL, of Johnson & Johnson Consumer Inc.
Strides Pharma Global Pte. Limited, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.
market outlook: Ahead of Market: 12 things that will decide stock action on Wednesday indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
The approved product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Deltasone tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co.
New Delhi, Feb 12: Drug firm Strides Pharma Science on Friday said its subsidiary, Strides Pharma Global Pte Ltd, has received approval from the US health
Strides Pharma to pursue portfolio maximisation in regulated markets
February 10, 2021
R Ananthanarayanan, Managing Director & CEO, Strides Pharma Sciences×
To develop products across multiple therapeutics segments
Strides Pharma Science Limited plans to pursue portfolio maximisation strategy across the regulated markets to unlock value. It is also exploring to develop a wide range of products across multiple therapeutics segments.
“Further to the Stelis demerger, Strides will keep open the option of adding injectables to its portfolio to complement its oral solid and topicals business as part of the portfolio maximisation strategy and will retain 100 per cent of the economics for the business,” the company’s spokesperson told